| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13156* | 2021 |
| Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients F Ghiringhelli, C Menard, PE Puig, S Ladoire, S Roux, F Martin, E Solary, ... Cancer immunology, immunotherapy 56, 641-648, 2007 | 1467 | 2007 |
| 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell–dependent antitumor immunity J Vincent, G Mignot, F Chalmin, S Ladoire, M Bruchard, A Chevriaux, ... Cancer research 70 (8), 3052-3061, 2010 | 1304 | 2010 |
| Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells F Chalmin, S Ladoire, G Mignot, J Vincent, M Bruchard, JP Remy-Martin, ... The Journal of clinical investigation 120 (2), 457-471, 2010 | 1120 | 2010 |
| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1022 | 2014 |
| An immunosurveillance mechanism controls cancer cell ploidy L Senovilla, I Vitale, I Martins, M Tailler, C Pailleret, M Michaud, L Galluzzi, ... Science 337 (6102), 1678-1684, 2012 | 439 | 2012 |
| Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 E Vacchelli, Y Ma, EE Baracco, A Sistigu, DP Enot, F Pietrocola, H Yang, ... Science 350 (6263), 972-978, 2015 | 433 | 2015 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 410 | 2021 |
| Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory … S Ladoire, L Arnould, L Apetoh, B Coudert, F Martin, B Chauffert, ... Clinical cancer research 14 (8), 2413-2420, 2008 | 386 | 2008 |
| Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer S Ladoire, F Martin, F Ghiringhelli Cancer Immunology, Immunotherapy 60, 909-918, 2011 | 380 | 2011 |
| Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression F Chalmin, G Mignot, M Bruchard, A Chevriaux, F Végran, A Hichami, ... Immunity 36 (3), 362-373, 2012 | 370 | 2012 |
| Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria PE Charles, S Ladoire, S Aho, JP Quenot, JM Doise, S Prin, NO Olsson, ... BMC infectious diseases 8, 1-8, 2008 | 341 | 2008 |
| Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia JP Quenot, S Ladoire, F Devoucoux, JM Doise, R Cailliod, N Cunin, ... Critical care medicine 35 (9), 2031-2036, 2007 | 299 | 2007 |
| Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? L Apetoh, S Ladoire, G Coukos, F Ghiringhelli Annals of Oncology 26 (9), 1813-1823, 2015 | 268 | 2015 |
| In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival S Ladoire, G Mignot, S Dabakuyo, L Arnould, L Apetoh, C Rébé, ... The Journal of pathology 224 (3), 389-400, 2011 | 268 | 2011 |
| Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX–bevacizumab drug treatment regimen E Limagne, R Euvrard, M Thibaudin, C Rébé, V Derangère, A Chevriaux, ... Cancer research 76 (18), 5241-5252, 2016 | 244 | 2016 |
| Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists T Yamazaki, D Hannani, V Poirier-Colame, S Ladoire, C Locher, A Sistigu, ... Cell Death & Differentiation 21 (1), 69-78, 2014 | 239 | 2014 |
| Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer B Guiu, JM Petit, F Bonnetain, S Ladoire, S Guiu, JP Cercueil, D Krausé, ... Gut 59 (3), 341-347, 2010 | 235 | 2010 |
| Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis C Guenancia, A Lefebvre, D Cardinale, AF Yu, S Ladoire, F Ghiringhelli, ... Journal of Clinical Oncology 34 (26), 3157-3165, 2016 | 195 | 2016 |
| Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ... Cancer 121 (15), 2586-2593, 2015 | 192 | 2015 |
Guido KroemerUniversité de Paris Cité, Hôpital Européen George Pompidou - AP-HP, Gustave Roussy Cancer CampusVerified email at inserm.fr
